Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing
- A. Cozzi-Lepri, M. Noguera-Julián, +375 authors S. Yerly
- Biology, Medicine
- The Journal of antimicrobial chemotherapy
- 21 October 2014
Pre-existing MVs more than double the risk of virological failure to first-line NNRTI-based ART and a dose–effect relationship between virology failure and mutational load was found. Expand
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment.
The relationship between HCV RNA increase and HIV RNA decrease indicates virus-virus interference, and an HCVRNA increase may cause significant liver damage only in a minority of patients. Expand
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment
INR are at higher risk of severe clinical events than responders and was only partially explained by current CD4+ cell count, which could be a marker of immune system malfunctioning, not completely captured by absolute CD4-cell count. Expand
Short-term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis.
- V. Puro, G. De Carli, +14 authors G. Ippolito
- Journal of biological regulators and homeostatic…
- 1 July 2001
The study indicates that the difference in the proportion of individuals developing side effects and discontinuing PEP is not significant, and the rate of discontinuation because of protease inhibitor side-effects does not justify per se the initial use of a less potent PEP regimen. Expand
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Combined virological and immunological data show definite antiviral activity in vivo for the combination of saquinavir at 600 mg plus zidovudine at 200 mg, which represents an advance in the treatment of HIV infection. Expand
Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals.
The results suggest that GBV-C coinfection may play a role in determining the rate of HIV rebound possibly by competing with HIV replication after HIV load has been successfully suppressed by HAART. Expand
Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy.
- B. Belfiori, P. Ciliegi, +4 authors D. Francisci
- Digestive and liver disease : official journal of…
- 1 April 2009
The results indicate that patients on maintenance treatment with methadone/buprenorphine can be treated for HCV, and the success rate was fairly good; tolerability and side effects were similar to those reported in non-IDU patients. Expand
Treatment for hepatitis C virus in injection drug users on opioid replacement therapy: a prospective multicentre study.
- B. Belfiori, A. Chiodera, +4 authors D. Francisci
- European journal of gastroenterology & hepatology
- 1 August 2007
Subjects with TNF-A-857TT and -1031TT genotypes showed the highest Helicobacter pylori seropositive rate compared with those with other genotypes. Expand
Recent Acquired STD and the Use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): Analysis of the Incidence of Newly Acquired Hepatitis B Infection and Syphilis
In this population, the use of HAART was not associated with a higher risk of newly acquired sexually transmitted diseases (STD), and Suppressive HAart was associated withA lower risk of HbsAg seroconversion. Expand